Major Depression. Severe depressive episode without psychotic symptoms
Conditions
Interventions
Intervention 1: The starting dose will be 25 mg/d serteralin -during the next month this dose gradually will reach to 150mg/d serteralin. Intervention 2: The starting dose will be 25 mg/d desipramine
Treatment - Drugs
The starting dose will be 25 mg/d serteralin -during the next month this dose gradually will reach to 150mg/d serteralin.
The starting dose will be 25 mg/d desipramine -during the next month this gradually dose will reach to 150mg/d desipramine.
The starting dose will37.5 mg/d bevenlafaxin, during the next month this dose gradually will reach to 150mg/d for venlafaxine.
Sponsors
Mashhad University of Medical Scinces
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: the patients or their family sign informed consent; Approving Mild To Moderate Alzheimer Disease Using Dsm?-TR Criteria By Psychiatrist; Out Patient Treatment; No Other Medication Except : H2 blockers – Anti Hypertensive Or Other Cardiovascular Drugs And Medications For Hypercholestrolemia. Exclusion Critera: Any Psychotropic Drugs (Except Achetyl – Aceterase Inhibitor ) During Last 2 Weeks; Substance Abuse; Any Other Psychiatric Illness; side effects of medication during study; the patient decided to leave the study.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Depression. Timepoint: weeks 2-4-8-12. Method of measurement: HRSD (Hamilton rating scale depression). | — |
Secondary
| Measure | Time frame |
|---|---|
| Mental Status. Timepoint: weeks 0,2,4,8,12. Method of measurement: Minimal Mental Status Examination (MMSE). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Ebrahim Abdollahian
Ibn-e-sina hospital, Mashhad University of Medical Scinces
Outcome results
None listed